UNIPATH LIMITED – Trademark Portfolio

Entity Type: 11

UNIPATH LIMITED holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 5 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 3 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include CLEARBLUE. The owner is based in BEDFORD.

NORSE ROAD

BEDFORD MK41 OQG , GB

7 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

UNIPATH LIMITED's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (5 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

1
Chemicals (3 filings)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

10
Medical Apparatus (2 filings)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does UNIPATH LIMITED have?

UNIPATH LIMITED has 7 U.S. trademarks filed with the USPTO. Of these, 1 registered, 6 cancelled.

What trademark classes does UNIPATH LIMITED file in?

UNIPATH LIMITED files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 1 (Chemicals), Class 10 (Medical Apparatus). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are UNIPATH LIMITED's most well-known trademarks?

UNIPATH LIMITED's registered trademark portfolio includes well-known marks such as CLEARBLUE. These are among 1 currently registered trademark in the portfolio.

What is UNIPATH LIMITED's trademark registration success rate?

UNIPATH LIMITED has a 14% trademark registration rate, with 1 out of 7 resolved applications resulting in successful registration. Currently, 0 applications are pending review.